VERU-111

For research use only. Not for therapeutic Use.

  • CAT Number: I018742
  • CAS Number: 1332881-26-1
  • Molecular Formula: C₂₁H₁₉N₃O₄
  • Molecular Weight: 377.39
  • Purity: ≥95%
Inquiry Now

VERU-111 (Cat No.:I018742) is a novel, orally active, and selective small molecule inhibitor of the tubulin polymerization pathway. It disrupts microtubule dynamics, leading to cell cycle arrest and inhibition of cell proliferation. VERU-111 has shown potent antiproliferative activity against various cancer cell lines, including taxane-resistant and multidrug-resistant tumors. It has also demonstrated efficacy in preclinical models of prostate, breast, and ovarian cancers. VERU-111 has the potential to overcome resistance to taxanes and other microtubule-targeting agents, making it a promising candidate for the treatment of chemotherapy-resistant cancers.


Catalog Number I018742
CAS Number 1332881-26-1
Molecular Formula C₂₁H₁₉N₃O₄
Purity ≥95%
IUPAC Name [2-(1H-indol-3-yl)-1H-imidazol-5-yl]-(3,4,5-trimethoxyphenyl)methanone
InChI InChI=1S/C21H19N3O4/c1-26-17-8-12(9-18(27-2)20(17)28-3)19(25)16-11-23-21(24-16)14-10-22-15-7-5-4-6-13(14)15/h4-11,22H,1-3H3,(H,23,24)
InChIKey WQGVHOVEXMOLOK-UHFFFAOYSA-N
SMILES COC1=CC(=CC(=C1OC)OC)C(=O)C2=CN=C(N2)C3=CNC4=CC=CC=C43
Reference

[1]. Wang Q, et al. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin. J Med Chem. 2019 Jul 12.<br>[2]. Qinghui Wang, et al. Discovery of ABI-231 analogs targeting the colchicine site in tubulin for advanced melanoma. Cancer Research 76(14 Supplement):4848-4848.<br>[3]. Vivek Kashyap, et al. ABI-231: A novel small molecule suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting Human papilloma virus (HPV) E6 and E7. Cancer Research 78(13 Supplement):679-679.<br>[4]. Kashyap VK, et al. Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res. 2019 Jan 23;38(1):29.

Request a Quote